The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms JR Schwartz, J Ma, J Kamens, T Westover, MP Walsh, SW Brady, ... Nature communications 12 (1), 985, 2021 | 51 | 2021 |
Integrative genomic analysis of pediatric myeloid-related acute leukemias identifies novel subtypes and prognostic indicators M Fornerod, J Ma, S Noort, Y Liu, MP Walsh, L Shi, S Nance, Y Liu, ... Blood cancer discovery 2 (6), 586-599, 2021 | 23 | 2021 |
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia JL Kamens, S Nance, C Koss, B Xu, A Cotton, JW Lam, EAR Garfinkle, ... nature communications 14 (1), 809, 2023 | 9 | 2023 |
A CRISPR/Cas9 engineered MplS504N mouse model recapitulates human myelofibrosis FRS Adriaanse, JL Kamens, P Vogel, SM Sakurada, SM Pruett-Miller, ... Leukemia 36 (10), 2535-2538, 2022 | 5 | 2022 |
The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nat Commun. 2021; 12: 985 JR Schwartz, J Ma, J Kamens, T Westover, MP Walsh, SW Brady, ... | 5 | |
Comprehensive genomic profiling of pediatric therapy-related myeloid neoplasms identifies Mecom dysregulation to be associated with poor outcome JR Schwartz, J Ma, MP Walsh, X Chen, T Lamprecht, J Kamens, ... Blood 134, 1394, 2019 | 4 | 2019 |
Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients A Reschke, RM Richards, SM Smith, AH Long, LJ Marks, L Schultz, ... Frontiers in oncology 12, 1033993, 2022 | 3 | 2022 |
Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma JL Kamens, J Dang, TI Shaw, AM Gout, S Newman, K Hagiwara, ... Molecular Cancer Research 21 (4), 301-306, 2023 | 2 | 2023 |
Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients S Ramakrishna, Z Good, M Desai, D Zamler, R Mancusi, J Mahdi, ... Cancer Research 83 (7_Supplement), 959-959, 2023 | 1 | 2023 |
DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS M Monje, J Mahdi, RG Majzner, K Yeom, LM Schultz, R Richards, ... Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas M Monje, J Mahdi, R Majzner, KW Yeom, L Schultz, RM Richards, ... medRxiv, 2024.06. 25.24309146, 2024 | | 2024 |
Loss of PTEN in Pediatric AML Confers Sensitivity to PARP Inhibition JL Kamens, A Cotton, JW Lam, J Dang, A Seth, BS Hansen, ... Blood 138, 3446, 2021 | | 2021 |
Genomic Analysis of Congenital Myeloid Sarcoma Identifies Significant Bone Marrow Involvement in the Absence of Morphologic Blasts J Kamens, J Dang, S Aldridge, J Ma, Y Wang, G Wu, V Leventaki, ... Blood 136, 41, 2020 | | 2020 |
MECOM DYSREGULATION VIA ENHANCER HIJACKING IN PEDIATRIC THERAPY-RELATED MYELOID NEOPLASMS J Schwartz, J Ma, J Kamens, T Lamprecht, M Walsh, X Chen, G Song, ... PEDIATRIC BLOOD & CANCER 67, S3-S4, 2020 | | 2020 |
Poly ADP Ribose Polymerase (PARP) Inhibitors and Their Role in the Treatment of Pediatric Acute Myeloid Leukemia J Kamens, A Seth, A Cottton, A Shelat, T Gruber Clinical Lymphoma, Myeloma and Leukemia 18, S199-S200, 2018 | | 2018 |
Hypocalcemic Tetany After Transfusion of a Small Amount of Blood Product A Sharma, TL Geiger, S Federico, J Kamens, F Giles, L Cunningham Journal of Pediatric Hematology/Oncology 39 (8), 629-632, 2017 | | 2017 |